Acticor Biotech (France) Performance
| ALACT Stock | EUR 0.29 0.02 7.41% |
On a scale of 0 to 100, Acticor Biotech holds a performance score of 2. The firm shows a Beta (market volatility) of -1.97, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Acticor Biotech are expected to decrease by larger amounts. On the other hand, during market turmoil, Acticor Biotech is expected to outperform it. Please check Acticor Biotech's value at risk, as well as the relationship between the skewness and day median price , to make a quick decision on whether Acticor Biotech's price patterns will revert.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Acticor Biotech SAS are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Acticor Biotech reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 7.6 M | |
| Total Cashflows From Investing Activities | -12 K |
Acticor |
Acticor Biotech Relative Risk vs. Return Landscape
If you would invest 42.00 in Acticor Biotech SAS on September 3, 2024 and sell it today you would lose (13.00) from holding Acticor Biotech SAS or give up 30.95% of portfolio value over 90 days. Acticor Biotech SAS is generating 0.5057% of daily returns and assumes 15.5713% volatility on return distribution over the 90 days horizon. Simply put, majority of traded equity instruments are less risky than Acticor on the basis of their historical return distribution, and most equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Acticor Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Acticor Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Acticor Biotech SAS, and traders can use it to determine the average amount a Acticor Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0325
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ALACT | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 15.57 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.51 actual daily | 10 90% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Acticor Biotech is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Acticor Biotech by adding it to a well-diversified portfolio.
Acticor Biotech Fundamentals Growth
Acticor Stock prices reflect investors' perceptions of the future prospects and financial health of Acticor Biotech, and Acticor Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Acticor Stock performance.
| Return On Equity | -3.33 | |||
| Return On Asset | -0.69 | |||
| Current Valuation | 76.26 M | |||
| Shares Outstanding | 10.52 M | |||
| Price To Earning | 35.47 X | |||
| Price To Book | 18.24 X | |||
| Price To Sales | 5.71 X | |||
| EBITDA | (11.92 M) | |||
| Cash And Equivalents | 571.18 K | |||
| Cash Per Share | 0.17 X | |||
| Total Debt | 2.2 M | |||
| Debt To Equity | 662.10 % | |||
| Book Value Per Share | 0.41 X | |||
| Cash Flow From Operations | (13.75 M) | |||
| Earnings Per Share | (1.34) X | |||
| Total Asset | 17.88 M | |||
About Acticor Biotech Performance
Assessing Acticor Biotech's fundamental ratios provides investors with valuable insights into Acticor Biotech's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Acticor Biotech is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Acticor Biotech SAS, a clinical stage biopharmaceutical company, develops drugs for the treatment of acute phase of thrombotic diseases. The company was founded in 2013 and is headquartered in Paris, France. ACTIPLAY is traded on Paris Stock Exchange in France.Things to note about Acticor Biotech SAS performance evaluation
Checking the ongoing alerts about Acticor Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Acticor Biotech SAS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Acticor Biotech SAS is way too risky over 90 days horizon | |
| Acticor Biotech SAS has some characteristics of a very speculative penny stock | |
| Acticor Biotech SAS appears to be risky and price may revert if volatility continues | |
| Acticor Biotech SAS has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| Net Loss for the year was (12.61 M) with profit before overhead, payroll, taxes, and interest of 320.18 K. | |
| Acticor Biotech SAS has accumulated about 571.18 K in cash with (13.75 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.17. |
- Analyzing Acticor Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Acticor Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Acticor Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Acticor Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Acticor Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Acticor Biotech's stock. These opinions can provide insight into Acticor Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Acticor Stock Analysis
When running Acticor Biotech's price analysis, check to measure Acticor Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acticor Biotech is operating at the current time. Most of Acticor Biotech's value examination focuses on studying past and present price action to predict the probability of Acticor Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acticor Biotech's price. Additionally, you may evaluate how the addition of Acticor Biotech to your portfolios can decrease your overall portfolio volatility.